Mesa Laboratories plans to provide full-year guidance in November with first-half results
Overview
US life science tools maker's fiscal Q1 revenue rose 1.0% year-over-year
Adjusted operating income excluding unusual items increased 19.5%
Net income fell 40.3% due to higher nonoperating expense
Result drivers
Divisional performance - Revenue growth was driven by Calibration Solutions and Biopharmaceutical Development divisions, while Sterilization and Disinfection Control declined due to fulfillment and delivery execution challenges; Clinical Genomics was flat with ongoing weakness in China
Gross margin variation - Gross profit margin rose in BPD, CS, and CG due to favorable product mix, supply chain efficiencies, and higher revenues on a partially fixed cost base, but declined in SDC due to lower revenues and product mix
Investment in SDC - Company increased investment in Sterilization and Disinfection Control to support future organic growth
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
MLAB•
